三子养亲汤合苓桂术甘汤治疗痰浊阻肺证慢阻肺患者的临床疗效研究

Clinical Study on the Efficacy of Sanzi Yangqin Decoction Combined with Linggui Zhugan Decoction in Treating COPD Patients with Phlegm-Turbidity Obstructing the Lung Syndrome

摘要: 目的：探讨三子养亲汤合苓桂术甘汤联合常规西医治疗对痰浊阻肺证慢性阻塞性肺疾病急性加重期(AECOPD)患者的临床疗效。方法：将76例AECOPD痰浊阻肺证患者随机分为观察组与对照组，各38例。对照组采用西医标准治疗，观察组在此基础上加用三子养亲汤合苓桂术甘汤，疗程10 d。比较两组治疗后的总有效率、中医证候积分、肺功能(FEV₁%pred)、动脉血气(PaO₂, PaCO₂)及炎症指标(IL-8, PCT)。结果：观察组总有效率为97.37%，显著高于对照组的78.95% (P < 0.05)。观察组中医证候积分、FEV₁%pred、PaO₂、PaCO₂、IL-8和PCT改善程度均优于对照组(均P < 0.05)。结论：三子养亲汤合苓桂术甘汤联合西医治疗能有效改善痰浊阻肺证AECOPD患者的临床症状、肺功能及血气指标，减轻炎症反应，疗效显著且安全性良好。

Abstract: Objective: To investigate the clinical efficacy of Sanzi Yangqin Decoction combined with Linggui Zhugan Decoction in the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) of phlegm-turbidity obstructing the lung syndrome. Methods: A total of 76 AECOPD patients with phlegm-turbidity obstructing the lung syndrome were randomly divided into an observation group and a control group, with 38 cases in each group. The control group received conventional Western medicine treatment, while the observation group was additionally treated with Sanzi Yangqin Decoction combined with Linggui Zhugan Decoction. The treatment course lasted for 10 days. The total effective rate, TCM syndrome score, lung function (FEV₁%pred), arterial blood gas parameters (PaO₂, PaCO₂), and inflammatory markers (IL-8, PCT) were compared between the two groups after treatment. Results: The total effective rate in the observation group was 97.37%, significantly higher than that in the control group (78.95%, P < 0.05). The improvement in TCM syndrome score, FEV₁%pred, PaO₂, PaCO₂, IL-8, and PCT in the observation group was superior to that in the control group (all P < 0.05). Conclusion: The combination of Sanzi Yangqin Decoction and Linggui Zhugan Decoction with conventional Western medicine can effectively improve clinical symptoms, lung function, and blood gas parameters, while reducing inflammatory reactions in AECOPD patients with phlegm-turbidity obstructing the lung syndrome. The treatment demonstrates significant efficacy and good safety.